CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Bought by Swiss National Bank

Swiss National Bank grew its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 1.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 159,100 shares of the company’s stock after acquiring an additional 1,500 shares during the period. Swiss National Bank owned about 0.19% of CRISPR Therapeutics worth $6,262,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of CRSP. Highline Wealth Partners LLC purchased a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at about $39,000. Western Pacific Wealth Management LP increased its position in CRISPR Therapeutics by 100.0% during the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after buying an additional 500 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of CRISPR Therapeutics in the third quarter worth $40,000. Spire Wealth Management lifted its position in shares of CRISPR Therapeutics by 303.7% in the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock valued at $78,000 after acquiring an additional 1,482 shares in the last quarter. Finally, MCF Advisors LLC acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter valued at $80,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Barclays upped their target price on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. The Goldman Sachs Group decreased their target price on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a research report on Thursday, February 13th. HC Wainwright reiterated a “buy” rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Morgan Stanley raised their price objective on CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a report on Friday, February 14th. Finally, Bank of America dropped their target price on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $73.11.

CRISPR Therapeutics Trading Up 0.1 %

Shares of NASDAQ CRSP opened at $41.22 on Monday. The stock has a fifty day moving average price of $43.09 and a 200 day moving average price of $45.37. The company has a market cap of $3.54 billion, a P/E ratio of -9.43 and a beta of 1.77. CRISPR Therapeutics AG has a 12-month low of $36.52 and a 12-month high of $73.09.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, sell-side analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Insider Activity

In other news, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the sale, the chief executive officer now directly owns 171,613 shares of the company’s stock, valued at approximately $9,473,037.60. The trade was a 9.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Julianne Bruno sold 1,198 shares of the business’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $50,819.16. Following the completion of the transaction, the chief operating officer now owns 8,263 shares in the company, valued at approximately $350,516.46. This trade represents a 12.66 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 32,381 shares of company stock worth $1,608,243 over the last 90 days. Company insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.